These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31999844)

  • 1. Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States.
    Li A; Carlson JJ; Kuderer NM; Schaefer JK; Li S; Garcia DA; Khorana AA; Carrier M; Lyman GH
    Cancer; 2020 Apr; 126(8):1736-1748. PubMed ID: 31999844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
    Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
    Muñoz A; Gallardo E; Agnelli G; Crespo C; Forghani M; Arumi D; Fernández de Cabo S; Soto J
    J Med Econ; 2022; 25(1):840-847. PubMed ID: 35703036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.
    Li A; Manohar PM; Garcia DA; Lyman GH; Steuten LM
    Thromb Res; 2019 Aug; 180():37-42. PubMed ID: 31200341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
    de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
    Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of rivaroxaban versus apixaban for the initial treatment of venous thromboembolism and extended prevention of recurrences in the UK.
    Folkerts K; Broughton J; Sheikh U; Mckaig S
    J Med Econ; 2019 Nov; 22(11):1179-1191. PubMed ID: 31433687
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China.
    Wu Y; Yin T; Jian G; Wan T; Zhou B
    Front Pharmacol; 2024; 15():1373333. PubMed ID: 39376608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
    Gulati S; Eckman MH
    Ann Intern Med; 2023 Jan; 176(1):1-9. PubMed ID: 36571839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
    Yan X; Gu X; Xu Z; Lin H; Wu B
    Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review.
    Al Mukdad M; Al-Badriyeh D; Elewa HF
    Clin Appl Thromb Hemost; 2019; 25():1076029619849103. PubMed ID: 31088296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery.
    Mahmoudi M; Sobieraj DM
    Pharmacotherapy; 2013 Dec; 33(12):1333-40. PubMed ID: 23625693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Oral Anticoagulants for Thromboprophylaxis in Patients with Cancer Receiving Chemotherapy: An Economic Evaluation in a Chinese Setting.
    Du J; Wu B
    Clin Drug Investig; 2020 Jul; 40(7):653-663. PubMed ID: 32445169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.
    Muñoz AJ; Ortega L; Gutiérrez A; Gallardo E; Rubio-Rodríguez D; Rubio-Terrés C; Morón B; García-Alfonso P; Soria JM
    J Med Econ; 2023; 26(1):1145-1154. PubMed ID: 37602646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
    Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
    Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Utility Analysis Comparing Direct Oral Anticoagulant and Low Molecular Weight Heparin Therapies for Secondary Prevention of Cancer-Associated Thrombosis.
    Shin YE; Kumar A; Hwang M; Mackey M; Wu WK
    Clin Drug Investig; 2022 Dec; 42(12):1075-1083. PubMed ID: 36315349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
    Preblick R; Kwong WJ; White RH; Goldhaber SZ
    Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
    Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
    CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.